Astria Therapeutics, Inc. (ATXS) Research

Astria Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, established in 2008. The firm specializes in identifying, advancing, and bringing to market treatments for uncommon and specialized allergic and immunological disorders across the United States. Its leading experimental drug, STAR-0215, is a monoclonal antibody that targets and inhibits plasma kallikrein. This candidate is presently undergoing preclinical development to address hereditary angioedema. The company adopted its current name, Astria Therapeutics, Inc., in September 2021, having previously operated as Catabasis Pharmaceuticals, Inc.

Market snapshot

Symbol
ATXS
Price
$12.58
Day change
0.00%
Market cap
$718.1M
P/E ratio
-5.88x
52-week range
3.555-13.29
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$19.40

Peer companies

  • Arvinas, Inc. (ARVN)
  • ArriVent BioPharma, Inc. Common Stock (AVBP)
  • Day One Biopharmaceuticals, Inc. (DAWN)
  • Ginkgo Bioworks Holdings, Inc. (DNA)
  • Erasca, Inc. (ERAS)
  • Iovance Biotherapeutics, Inc. (IOVA)
  • MBX Biosciences, Inc. Common Stock (MBX)
  • MeiraGTx Holdings plc (MGTX)

Recent insider activity

  • Violin Jonathan — D-Return (14100 shares) on 2026-01-23
  • Violin Jonathan — D-Return (8333 shares) on 2026-01-23
  • Violin Jonathan — D-Return (14100 shares) on 2026-01-23
  • Violin Jonathan — D-Return (263321 shares) on 2026-01-23
  • Violin Jonathan — D-Return (14166 shares) on 2026-01-23

Open Astria Therapeutics, Inc. (ATXS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.